AU2002365510A1 - Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies - Google Patents

Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies

Info

Publication number
AU2002365510A1
AU2002365510A1 AU2002365510A AU2002365510A AU2002365510A1 AU 2002365510 A1 AU2002365510 A1 AU 2002365510A1 AU 2002365510 A AU2002365510 A AU 2002365510A AU 2002365510 A AU2002365510 A AU 2002365510A AU 2002365510 A1 AU2002365510 A1 AU 2002365510A1
Authority
AU
Australia
Prior art keywords
allergies
treatment
autoimmune diseases
sulfone derivatives
sulfone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002365510A
Other languages
English (en)
Inventor
Desmond John Best
Gordon Bruton
Barry Sidney Orlek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002365510A1 publication Critical patent/AU2002365510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
AU2002365510A 2001-11-27 2002-11-25 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies Abandoned AU2002365510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0128376.1A GB0128376D0 (en) 2001-11-27 2001-11-27 Novel compounds
GB0128376.1 2001-11-27
PCT/EP2002/013263 WO2003045922A1 (en) 2001-11-27 2002-11-25 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies

Publications (1)

Publication Number Publication Date
AU2002365510A1 true AU2002365510A1 (en) 2003-06-10

Family

ID=9926523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365510A Abandoned AU2002365510A1 (en) 2001-11-27 2002-11-25 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies

Country Status (11)

Country Link
US (1) US7038055B2 (enExample)
EP (1) EP1448529B1 (enExample)
JP (1) JP2005513034A (enExample)
AR (1) AR037426A1 (enExample)
AT (1) ATE299497T1 (enExample)
AU (1) AU2002365510A1 (enExample)
DE (1) DE60205035T2 (enExample)
ES (1) ES2243783T3 (enExample)
GB (1) GB0128376D0 (enExample)
TW (1) TW200303746A (enExample)
WO (1) WO2003045922A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DK1001930T3 (da) * 1997-07-31 2003-03-24 Abbott Lab N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
DE69934094T2 (de) 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
AU2001267468A1 (en) * 2000-05-25 2001-12-03 Smithkline Beecham P.L.C. Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides

Also Published As

Publication number Publication date
WO2003045922A1 (en) 2003-06-05
ES2243783T3 (es) 2005-12-01
EP1448529A1 (en) 2004-08-25
DE60205035D1 (de) 2005-08-18
DE60205035T2 (de) 2005-12-29
JP2005513034A (ja) 2005-05-12
US7038055B2 (en) 2006-05-02
TW200303746A (en) 2003-09-16
US20050070572A1 (en) 2005-03-31
AR037426A1 (es) 2004-11-10
EP1448529B1 (en) 2005-07-13
GB0128376D0 (en) 2002-01-16
ATE299497T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001286171A1 (en) Human cDNAs and proteins and uses thereof
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002314466A1 (en) Withasol and methods of use
AU2002346504A1 (en) Therapeutic protein and treatments
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU2002359512A1 (en) Belts and methods of use thereof
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
AU2002252976A1 (en) Hydrazones and their therapeutic use
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
HUP0303612A3 (en) Bicyclic guanidine derivatives and their therapeutic use
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
EP1392460A4 (en) AMINOSILANOL HYDROFLUORIDES AND THEIR USE
AU2003217432A1 (en) Angiopoietin-1 in the treatment of disease
AU2003208289A1 (en) Deuterated spirocyclopentanimidazolinones and the use thereof in the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase